Trexquant Investment LP Acquires New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Trexquant Investment LP purchased a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 14,129 shares of the company's stock, valued at approximately $1,195,000.

Other institutional investors have also recently made changes to their positions in the company. Captrust Financial Advisors purchased a new stake in Axsome Therapeutics in the third quarter worth $514,000. Barclays PLC lifted its holdings in Axsome Therapeutics by 279.6% during the 3rd quarter. Barclays PLC now owns 61,785 shares of the company's stock valued at $5,552,000 after buying an additional 45,509 shares in the last quarter. Geode Capital Management LLC boosted its position in Axsome Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 908,459 shares of the company's stock valued at $81,659,000 after buying an additional 23,564 shares during the period. Franklin Resources Inc. boosted its position in Axsome Therapeutics by 47.5% in the 3rd quarter. Franklin Resources Inc. now owns 160,534 shares of the company's stock valued at $13,713,000 after buying an additional 51,696 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Axsome Therapeutics by 14.9% during the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock worth $19,062,000 after acquiring an additional 27,534 shares during the period. Institutional investors own 81.49% of the company's stock.

Axsome Therapeutics Trading Down 0.5 %

Shares of AXSM traded down $0.53 during midday trading on Wednesday, reaching $103.30. The company had a trading volume of 84,469 shares, compared to its average volume of 679,240. The firm has a 50 day simple moving average of $119.19 and a 200-day simple moving average of $102.18. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The stock has a market cap of $5.04 billion, a PE ratio of -17.25 and a beta of 0.88. Axsome Therapeutics, Inc. has a 1-year low of $64.11 and a 1-year high of $139.13.

Remove Ads

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. Research analysts forecast that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on AXSM. Leerink Partners boosted their price objective on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an "outperform" rating in a research note on Monday, February 10th. Robert W. Baird boosted their target price on Axsome Therapeutics from $132.00 to $160.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. Royal Bank of Canada boosted their price target on Axsome Therapeutics from $143.00 to $192.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 19th. Bank of America lifted their target price on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. Finally, William Blair reissued an "outperform" rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $169.80.

Insider Buying and Selling at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 22.40% of the stock is currently owned by corporate insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.